Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenagamtide cardiovascular outcomes study in established ASCVD with overweight or obesity
NL-OMON61625Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, Overweight and obesity comparing Zenagamtide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first 4-point MACE. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on NL-OMON61625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61625.